Elucidation of molecular targets based on epithelial-mesenchymal transition for the treatment of renal cell carcinoma

阐明基于上皮间质转化的肾细胞癌治疗分子靶点

• 批准号: 24390374
• 负责人: OYA Mototsugu
• 金额: $ 11.73万
• 依托单位: Keio University
• 依托单位国家: 日本
• 项目类别: Grant-in-Aid for Scientific Research (B)
• 财政年份: 2012
• 资助国家: 日本
• 起止时间: 2012-04-01 至 2015-03-31
• 项目状态: 已结题
• 来源: https://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-24390374/
• 关键词: 腎細胞癌; 分子標的治療; 薬剤耐性; CD44; mTOR

项目成果

Efficacy of axitinib in patients with metastatic renal cell carcinoma previously treated with both VEGFR-TKI and mTORI.

阿西替尼对既往接受过 VEGFR-TKI 和 mTORI 治疗的转移性肾细胞癌患者的疗效。

• 发表时间: 2014
• 作者: Mizuno R ;Kosaka T;Mikami S;Oya M
• 通讯作者: Oya M

Bisebromoamide, as a novel molecular target drug inhibiting phosphorylation of both extracellular signal-regulated kinase and akt in renal cell carcinoma.

双司溴酰胺作为一种新型分子靶向药物，可抑制肾细胞癌中细胞外信号调节激酶和 akt 的磷酸化。

• 发表时间: 2012
• 作者: Suzuki K;Mizuno R;Oya M;et al.
• 通讯作者: et al.

Renal angiomyolipoma: a radiological classification and update on recent developments in diagnosis and management.

• DOI: 10.1007/s00261-014-0083-3
• 发表时间: 2014-06
• 期刊: ABDOMINAL IMAGING
• 作者: Jinzaki, Masahiro;Silverman, Stuart G.;Akita, Hirotaka;Nagashima, Yoji;Mikami, Shuji;Oya, Mototsugu
• 通讯作者: Oya, Mototsugu

C-REACTIVE protein indepently predicts the prognosis of patients with upper tract urothelial carcinoma treated with radical nephroureterectomy: A multiinstitutional study.

C-反应蛋白独立预测接受根治性肾输尿管切除术治疗的上尿路尿路上皮癌患者的预后：一项多机构研究。

• 发表时间: 2013
• 作者: Obata J;Kikuchi E;Tanaka N;Ishioka K;Shirotake S;Matsumoto K;Kobayashi H;Miyazaki Y;Ide H;Hayakawa N;Ito Y;Kanao K;Miyajima A;Momma T;Nakagawa K;Ueno M;Oya M.
• 通讯作者: Oya M.

Long-term outcomes of children with Xp11.2 translocation renal cell carcinoma.

Xp11.2 易位肾细胞癌儿童的长期结局。

• 发表时间: 2012
• 作者: Asanuma H;Mizuno R;Oya M;et al.
• 通讯作者: et al.